បានធ្វើបច្ចុប្បន្នភាពចុងក្រោយ៖ ខែឧសភា 18, 2026
HPV or Human papillomavirus is one of the most common viral infections transmitted through sexual contact. It can lead to serious diseases including cervical cancer in females, penile cancer in males, and anal or oropharyngeal cancer in both sexes.
The US CDC reports 14 million new infections every year. Over 100 subtypes have been identified. Sexually active individuals are at risk of contracting at least one subtype in their lifetime even with a single partner and condom use. Most infections are asymptomatic and resolve within 2 years – 90% disappear without treatment. Only a small number persist and progress to cancer.
Not all subtypes cause cancer. Most cause only cosmetic conditions like genital warts. HPV types 16 and 18 are responsible for more than 70% of all cervical cancer cases.
There are 3 HPV vaccinations approved by US FDA and CDC:
- Gardasil – Protects against 4 HPV strains causing 70% of cervical cancers and most genital warts. Suitable for both males and females.
- Cervarix – Protects against 2 HPV strains causing 70% of cervical cancers. Suitable for females only.
- Gardasil ៩ – Protects against 9 HPV strains causing 90% of cervical cancers and most genital warts. Suitable for both males and females. This is currently the preferred vaccine.
Vaccination is most effective when given before first sexual activity. US CDC recommendation: 2 doses for those under 15 years old, and 3 doses for those 15 years and above. Vaccination also benefits older individuals by reducing genital wart recurrence. Studies confirm that protection from the vaccine introduced in 2006 remains durable over many years.
If you have questions or any assistance, please drop by ការិយាល័យរបស់ខ្ញុំ.
If you are considering HPV vaccination for yourself or a family member, or want to discuss genital warts or HPV-related concerns, Dr. Soarawee Weerasopone offers specialist consultations at Bangkok Hospital Headquarters. កក់ការពិគ្រោះយោបល់.
Frequently Asked Questions about HPV Vaccination
Human papillomavirus (HPV) is the most common sexually transmitted viral infection worldwide. While most infections resolve on their own within 2 years, persistent infection with high-risk strains – particularly types 16 and 18 – can lead to cervical cancer in women, penile cancer in men, and anal or oropharyngeal cancer in both sexes. Low-risk strains cause genital warts, which are not cancerous but are cosmetically distressing.
Yes. HPV vaccination is recommended for both males and females. In men, it reduces the risk of penile cancer, anal cancer, oropharyngeal cancer, and genital warts. Gardasil and Gardasil 9 are approved for use in males. Vaccinating men also reduces HPV transmission to female partners, contributing to population-level cancer prevention.
HPV vaccination is most effective when given before the first sexual exposure. The CDC recommends vaccination starting at age 11–12, ideally before adolescence. The schedule is 2 doses for those under 15, and 3 doses for those 15 and above. Vaccination can still provide benefit in older individuals who have not been previously vaccinated, particularly for genital wart prevention.
Gardasil protects against 4 HPV strains (types 6, 11, 16, 18) and is suitable for both sexes. Cervarix protects against 2 strains (types 16, 18) and is for females only. Gardasil 9 is the most comprehensive vaccine, covering 9 strains and protecting against 90% of cervical cancers and most genital warts. It is currently the preferred vaccine for both males and females.
Yes. While condoms significantly reduce HPV transmission risk, they do not provide complete protection because HPV can infect skin areas not covered by a condom. Studies show that even individuals with a single lifetime partner who consistently use condoms can contract HPV. This is why vaccination is strongly recommended in addition to safe sexual practices, as it provides the most reliable protection against high-risk strains.
ការបដិសេធ៖ ខ្លឹមសារនេះត្រូវបានសរសេរ និងពិនិត្យដោយលោកវេជ្ជបណ្ឌិត Soarawee Weerasopone ដែលជាគ្រូពេទ្យឯកទេសខាងប្រព័ន្ធទឹកនោមដែលមានវិញ្ញាបនបត្រនៅទីស្នាក់ការកណ្តាលមន្ទីរពេទ្យបាងកក។ វាត្រូវបានបម្រុងទុកសម្រាប់គោលបំណងអប់រំតែប៉ុណ្ណោះ ហើយមិនមែនជាដំបូន្មានផ្នែកវេជ្ជសាស្ត្រទេ។ តែងតែពិគ្រោះជាមួយអ្នកជំនាញថែទាំសុខភាពដែលមានសមត្ថភាពមុនពេលចាប់ផ្តើមការព្យាបាលណាមួយឡើយ។.
សរសេរ និងពិនិត្យផ្នែកវេជ្ជសាស្ត្រដោយ៖ វេជ្ជបណ្ឌិត សូរ៉ាវី វីរ៉ាសូផូន (វេជ្ជបណ្ឌិត ប៉ុម) — អ្នកជំនាញខាងប្រព័ន្ធទឹកនោមដែលមានវិញ្ញាបនបត្រពីក្រុមប្រឹក្សាភិបាល ទីស្នាក់ការកណ្តាលមន្ទីរពេទ្យបាងកក។ អ្នកស្រាវជ្រាវអន្តរជាតិ៖ មហាវិទ្យាល័យវេជ្ជសាស្ត្របៃឡ័រ (សហរដ្ឋអាមេរិក) · សាកលវិទ្យាល័យជូនថេនដូ (ជប៉ុន) · មន្ទីរពេទ្យអនុស្សាវរីយ៍ឆាងហ្គុង (តៃវ៉ាន់)។.
លោកវេជ្ជបណ្ឌិត សូរ៉ាវី វីរ៉ាសូផូន (លោកវេជ្ជបណ្ឌិត ប៉ុម) គឺជាគ្រូពេទ្យឯកទេសខាងប្រព័ន្ធទឹកនោមដែលមានវិញ្ញាបនបត្រនៅទីស្នាក់ការកណ្តាលមន្ទីរពេទ្យបាងកក ដែលមានជំនាញខាងសុខភាពបុរស ការវះកាត់ដោយមនុស្សយន្ត (ប្រព័ន្ធដាវីនស៊ី) និងការព្យាបាលគ្រួសក្នុងតម្រងនោម។ លោកបានបញ្ចប់អាហារូបករណ៍អន្តរជាតិនៅមហាវិទ្យាល័យវេជ្ជសាស្ត្របៃឡ័រ (សហរដ្ឋអាមេរិក) មន្ទីរពេទ្យសាកលវិទ្យាល័យជូនថេនដូ (ជប៉ុន) និងមន្ទីរពេទ្យអនុស្សាវរីយ៍ឆាងហ្គុង (តៃវ៉ាន់)។ ខ្លឹមសារវេជ្ជសាស្ត្រទាំងអស់នៅលើគេហទំព័រនេះត្រូវបានសរសេរ និងពិនិត្យដោយលោកវេជ្ជបណ្ឌិត សូរ៉ាវី ដោយផ្អែកលើបទពិសោធន៍គ្លីនិក និងការបណ្តុះបណ្តាលអន្តរជាតិរបស់លោក។.
ភាសាខ្មែរ 
English 
ไทย 
বাংলা 
日本語 
ဗမာစာ 
العربية 
Français 
简体中文 
Русский 
한국어 
Deutsch 
Italiano
ការឆ្លើយតបមួយ